[go: up one dir, main page]

DE69940635D1 - COPOLYMER COMPOSITIONS FOR ORAL ADMINISTRATION - Google Patents

COPOLYMER COMPOSITIONS FOR ORAL ADMINISTRATION

Info

Publication number
DE69940635D1
DE69940635D1 DE69940635T DE69940635T DE69940635D1 DE 69940635 D1 DE69940635 D1 DE 69940635D1 DE 69940635 T DE69940635 T DE 69940635T DE 69940635 T DE69940635 T DE 69940635T DE 69940635 D1 DE69940635 D1 DE 69940635D1
Authority
DE
Germany
Prior art keywords
oral administration
copolymer compositions
compositions
poly
oral delivery
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69940635T
Other languages
German (de)
Inventor
Alexander V Kabanov
Valery Y Alakov
Elena V Batrakova
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Supratek Pharma Inc
Original Assignee
Supratek Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Supratek Pharma Inc filed Critical Supratek Pharma Inc
Application granted granted Critical
Publication of DE69940635D1 publication Critical patent/DE69940635D1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Dispersion Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Compositions for oral delivery having a biological agent or protein, peptide, or derivative thereof, and a poly(oxyethylene)-poly(oxypropylene) block copolymer. The compositions are useful in oral delivery of numerous agents. The invention also encompasses methods of treatment using the same.
DE69940635T 1998-02-06 1999-02-05 COPOLYMER COMPOSITIONS FOR ORAL ADMINISTRATION Expired - Lifetime DE69940635D1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/019,648 US6277410B1 (en) 1992-10-08 1998-02-06 Copolymer compositions for oral delivery
PCT/US1999/002538 WO1999039731A1 (en) 1998-02-06 1999-02-05 Copolymer compositions for oral delivery

Publications (1)

Publication Number Publication Date
DE69940635D1 true DE69940635D1 (en) 2009-05-07

Family

ID=21794304

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69940635T Expired - Lifetime DE69940635D1 (en) 1998-02-06 1999-02-05 COPOLYMER COMPOSITIONS FOR ORAL ADMINISTRATION

Country Status (8)

Country Link
US (2) US6277410B1 (en)
EP (1) EP1053010B1 (en)
JP (1) JP4685237B2 (en)
AT (1) ATE426397T1 (en)
AU (1) AU2496199A (en)
CA (1) CA2319057C (en)
DE (1) DE69940635D1 (en)
WO (1) WO1999039731A1 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6093391A (en) * 1992-10-08 2000-07-25 Supratek Pharma, Inc. Peptide copolymer compositions
US6277410B1 (en) * 1992-10-08 2001-08-21 Supratek Pharma Inc. Copolymer compositions for oral delivery
US6153193A (en) * 1993-04-28 2000-11-28 Supratek Pharma Inc. Compositions for targeting biological agents
US6353055B1 (en) 1994-11-18 2002-03-05 Supratek Pharma Inc. Polynucleotide compositions
EP1563850A3 (en) * 2000-02-23 2008-02-20 Pfizer Products Inc. Method of increasing the bioavailability and tissue penetration of azithromycin
IL141438A0 (en) * 2000-02-23 2002-03-10 Pfizer Prod Inc Method of increasing the bioavailability and tissue penetration of azithromycin
US7256180B2 (en) 2000-04-28 2007-08-14 Supratek Pharma Inc. Compositions and methods for inducing activation of dendritic cells
JP2004509838A (en) * 2000-04-28 2004-04-02 スプラテック　ファーマ　インコーポレイティド Compositions and methods for inducing dendritic cell activation
ATE401095T1 (en) * 2000-05-26 2008-08-15 Frohwitter Bernhard AGENTS FOR MAINTAINING AND/OR CORRECTING BLOOD GLUCOSE CONCENTRATION
US6861431B2 (en) 2001-03-23 2005-03-01 The Board Of Trustees Of The University Of Illinois Compounds capable of modulating the activity of multidrug transporters and therapeutic use of the same
GB0131112D0 (en) * 2001-12-31 2002-02-13 Univ London Pharmacy Block copolymers
US20040220283A1 (en) * 2002-07-29 2004-11-04 Transform Pharmaceuticals, Inc. Aqueous 2,6-diisopropylphenol pharmaceutical compositions
KR101145692B1 (en) * 2002-07-29 2012-05-25 트렌스폼 파마수티컬스 인코퍼레이티드 Aqueous 2,6-diisopropylphenol pharmaceutical compositions
US7550155B2 (en) * 2002-07-29 2009-06-23 Transform Pharmaceuticals Inc. Aqueous pharmaceutical compositions of 2,6-diisopropylphenol (propofol) and their uses
LT2891666T (en) 2002-10-16 2017-10-10 Purdue Pharma L.P. Antibodies that bind cell-associated CA 125/O722P and methods of use thereof
US7422875B2 (en) * 2004-07-20 2008-09-09 Board Of Regents Of The University Of Nebraska Compositions and methods for increasing protein production
US8017151B2 (en) * 2004-09-07 2011-09-13 Board Of Regents Of The University Of Nebraska By And Behalf Of The University Of Nebraska Medical Center Amphiphilic polymer-protein conjugates and methods of use thereof
US8168222B2 (en) * 2004-09-07 2012-05-01 Board Of Regents Of The University Of Nebraska Amphiphilic polymer-protein conjugates and methods of use thereof
WO2006099175A2 (en) * 2005-03-11 2006-09-21 Euro-Celtique S.A. Compositions comprising an anti-ca125 antibody and a cytotoxic compound and their use for the treatment of cancer
AU2007204950A1 (en) * 2006-01-10 2007-07-19 Innovaform Technologies, Llc Pesticide delivery system
US8148338B2 (en) * 2006-02-22 2012-04-03 Supratek Pharma Inc. Doxorubicin formulations for anti-cancer use
RU2409363C9 (en) * 2009-09-18 2013-12-10 Всеволод Иванович Киселев Pharmaceutical compositions for peroral delivery of diindolylmethane (dim) and methods for application of these compositions
WO2013082299A1 (en) 2011-11-29 2013-06-06 Als Therapy Development Institute Targeting of t-lymphocytes to treat amyotrophic lateral sclerosis
US8912215B2 (en) 2011-12-13 2014-12-16 Everon Biosciences, Inc. Rapamycin composition
WO2023220641A2 (en) 2022-05-11 2023-11-16 Juno Therapeutics, Inc. Methods and uses related to t cell therapy and production of same

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4027013A (en) 1976-01-22 1977-05-31 William L. Wilson Clottable fibrinogen free factor VIII and albumin product and process
US4188373A (en) 1976-02-26 1980-02-12 Cooper Laboratories, Inc. Clear, water-miscible, liquid pharmaceutical vehicles and compositions which gel at body temperature for drug delivery to mucous membranes
US4106474A (en) 1977-03-17 1978-08-15 Modine Manufacturing Company Heat conserving space heater
US4865835A (en) 1982-06-02 1989-09-12 Begent Richard H J Diagnosis and treatment of tumors
DE3380726D1 (en) 1982-06-24 1989-11-23 Japan Chem Res Long-acting composition
US4474752A (en) 1983-05-16 1984-10-02 Merck & Co., Inc. Drug delivery system utilizing thermosetting gels
ES532317A0 (en) * 1983-05-16 1985-11-16 Merck & Co Inc A PHARMACEUTICAL COMPOSITION
US4485457A (en) 1983-05-31 1984-11-27 Cbs Inc. Memory system including RAM and page switchable ROM
US4772466A (en) 1983-08-22 1988-09-20 Syntex (U.S.A.) Inc. Vaccines comprising polyoxypropylene-polyoxyethylene block polymer based adjuvants
US4957735A (en) 1984-06-12 1990-09-18 The University Of Tennessee Research Corporation Target-sensitive immunoliposomes- preparation and characterization
JPS61103836A (en) 1984-10-24 1986-05-22 Green Cross Corp:The Fibronectin preparations
US5234683A (en) 1985-06-18 1993-08-10 Emory University Method of stimulating the immune system
US5494660A (en) 1985-06-18 1996-02-27 Emory University Method for inhibiting microbial binding to surfaces
US5114708A (en) 1985-06-18 1992-05-19 Emory University Method for stimulating growth in animals
US5466445A (en) 1985-06-18 1995-11-14 Emory University Methods for reducing salmonella in chickens
US5183687A (en) 1985-06-18 1993-02-02 Emory University Method of treating poultry for coccidiosis
EP0378246B1 (en) * 1985-06-18 1992-03-11 Emory University Biologically active copolymers
AU6073386A (en) * 1985-07-30 1987-02-05 International Minerals & Chemical Corporation Stabilization of growth promoting hormones
US5250294A (en) 1986-05-15 1993-10-05 Emory University Improved perfusion medium for transplantation of organs
US4997644A (en) 1986-05-15 1991-03-05 Emory University Method of treating adult respiratory distress syndrome
US4837014A (en) 1986-05-15 1989-06-06 Emory University An improved method of treating sickle cell anemia
US5078995A (en) 1986-05-15 1992-01-07 Emory University Fibrionolytic composition
US5064643A (en) 1986-05-15 1991-11-12 Emory University Method for treating sickle cell disease
US4879109A (en) 1986-05-15 1989-11-07 Emory University Method for treating burns
US5152979A (en) 1986-05-15 1992-10-06 Emory University Method for treating vascular obstructions caused by abnormal cells
US5648071A (en) * 1986-05-15 1997-07-15 Emory University Method of treating tumors
US5198211A (en) 1986-05-15 1993-03-30 Emory University Method of treating myocardial damage
US5028599A (en) 1986-05-15 1991-07-02 Emory University Method of treating mycardial damage
US5071649A (en) 1986-05-15 1991-12-10 Emory University Method of preventing blockage in catheters
US4801452A (en) 1986-05-15 1989-01-31 Hunter Robert L Fibrinolytic composition
US5041288A (en) 1986-05-15 1991-08-20 Emory University Method of treating tissue damaged by reperfusion injury
US5032394A (en) 1986-05-15 1991-07-16 Emory University Method of treating burns
US5039520A (en) 1986-05-15 1991-08-13 Emory University Plasma extender
US5017370A (en) 1986-05-15 1991-05-21 Emory University Improved method of performing angioplasty procedures
US5240701A (en) 1986-05-15 1993-08-31 Emory University Method of performing angioplasty procedures
US4897263A (en) 1986-05-15 1990-01-30 Emory University Methods and compositions for treatment of pathological hydrophobic interactions in biological fluids
US5089260A (en) 1986-05-15 1992-02-18 Emory University Method of treating ischemic tissue
US5080894A (en) 1986-05-15 1992-01-14 Emory University Method and composition for reducing tissue damage
US4937070A (en) 1986-05-15 1990-06-26 Emory University Methods and compositions for treatment of pathological hydrophobic interactions in biological fluids
US5182106A (en) 1986-05-15 1993-01-26 Emory University Method for treating hypothermia
US5030448A (en) 1986-05-15 1991-07-09 Emory University Method of delivering drugs to damaged or diseased tissue
US5240702A (en) 1986-05-15 1993-08-31 Emory University Method of treating stroke
US4873083A (en) 1986-05-15 1989-10-10 Emory University Fibrinolytic composition
US5047236A (en) 1986-05-15 1991-09-10 Emory University Method of treating stroke
US4882168A (en) 1986-09-05 1989-11-21 American Cyanamid Company Polyesters containing alkylene oxide blocks as drug delivery systems
EP0283505B1 (en) * 1986-09-22 1994-07-06 Emory University Vaccine and method of preparation
US5554372A (en) * 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
US5567859A (en) * 1991-03-19 1996-10-22 Cytrx Corporation Polyoxypropylene/polyoxyethylene copolymers with improved biological activity
AU1396588A (en) * 1987-02-20 1988-09-14 Emory University Antiinfective compounds and method of use
US5674911A (en) * 1987-02-20 1997-10-07 Cytrx Corporation Antiinfective polyoxypropylene/polyoxyethylene copolymers and methods of use
CA1335879C (en) 1987-07-27 1995-06-13 Bruce Andrew Cornell Receptor membranes
US4853228A (en) 1987-07-28 1989-08-01 Micro-Pak, Inc. Method of manufacturing unilamellar lipid vesicles
IE911403A1 (en) * 1990-04-26 1991-11-06 Cytrx Corp Compositions and method for topical treatment of damaged or¹diseased tissue
NZ238731A (en) * 1990-06-27 1996-02-27 Univ Emory Vaccine adjuvant compositions comprising ethyleneoxy-propyleneoxy-ethyleneoxy block copolymer or a non-toxic lipopolysaccharide
US5399363A (en) * 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5696298A (en) * 1991-03-19 1997-12-09 Cytrx Corporation Polyoxypropylene/polyoxyethylene copolymers with improved biological activity
DE69230372T2 (en) * 1991-03-19 2000-06-15 Cytrx Corp., Norcross POLYOXYPROPYLEN / POLYOXYETHYLEN COPOLYMERE WITH IMPROVED BIOLOGICAL ACTIVITY
US5622649A (en) * 1991-06-27 1997-04-22 Emory University Multiple emulsions and methods of preparation
US5531925A (en) 1991-10-04 1996-07-02 Gs Biochem Ab Particles, method of preparing said particles and uses thereof
US5681812A (en) * 1991-12-10 1997-10-28 Rush Presbyterian-St. Luke's Medical Center Methods and compositions for reducing multidrug resistance
US5470568A (en) 1992-02-13 1995-11-28 Arch Development Corporation Methods and compositions of a polymer (poloxamer) for cell repair
US5573934A (en) 1992-04-20 1996-11-12 Board Of Regents, The University Of Texas System Gels for encapsulation of biological materials
KR940003548U (en) 1992-08-14 1994-02-21 김형술 Laundry dryer
US6153193A (en) 1993-04-28 2000-11-28 Supratek Pharma Inc. Compositions for targeting biological agents
US6277410B1 (en) 1992-10-08 2001-08-21 Supratek Pharma Inc. Copolymer compositions for oral delivery
US5840319A (en) 1992-10-08 1998-11-24 Alakhov; Valery Yu Biological agent compositions
JPH08506319A (en) 1992-10-08 1996-07-09 ヴァレリ ユ． アラホフ Anti-neoplastic composition incorporated in micelles
EP0682524B1 (en) 1993-02-02 2001-10-04 XOMA Technology Ltd. Pharmaceutical compositions containing bactericidal permeability increasing protein and a surfactant
IL106578A (en) 1993-08-03 2000-08-13 Yissum Res Dev Co Pharmaceutical compositions for drug targeting
US5417982A (en) 1994-02-17 1995-05-23 Modi; Pankaj Controlled release of drugs or hormones in biodegradable polymer microspheres
US5401296A (en) 1994-06-28 1995-03-28 Martenson; Irvin Precious metal extraction process
US5656611A (en) 1994-11-18 1997-08-12 Supratek Pharma Inc. Polynucleotide compositions
US6040295A (en) 1995-01-13 2000-03-21 Genemedicine, Inc. Formulated nucleic acid compositions and methods of administering the same for gene therapy
AUPN801296A0 (en) * 1996-02-12 1996-03-07 Csl Limited Stabilised growth hormone formulation and method of preparation thereof
JP4117922B2 (en) * 1996-03-28 2008-07-16 武田薬品工業株式会社 Sustained release preparation and production method thereof

Also Published As

Publication number Publication date
WO1999039731A1 (en) 1999-08-12
AU2496199A (en) 1999-08-23
EP1053010B1 (en) 2009-03-25
ATE426397T1 (en) 2009-04-15
US6277410B1 (en) 2001-08-21
JP4685237B2 (en) 2011-05-18
CA2319057A1 (en) 1999-08-12
JP2002502825A (en) 2002-01-29
CA2319057C (en) 2010-05-04
EP1053010A4 (en) 2002-08-21
EP1053010A1 (en) 2000-11-22
US6387406B1 (en) 2002-05-14

Similar Documents

Publication Publication Date Title
ATE426397T1 (en) COPOLYMER COMPOSITIONS FOR ORAL ADMINISTRATION
TR200100054T2 (en) Paroxetine methanesulfonate
MXPA03009772A (en) Methods and compositions for treating oral and eosophageal lesions.
BR9916857A (en) 4 heteroaryl diarylamines
DK1117440T3 (en) Pharmaceutical compositions containing paclitaxel
DK0839026T3 (en) Micellar polyether block copolymer compositions for targeting biological agents
TR200002299T2 (en) Epothilon compositions.
MXPA03010085A (en) Composition and methods for treatment of hyperplasia.
BR0308090A (en) cytotoxic or therapeutic agent conjugates and biologically active peptides
MY136095A (en) Use of human anti-ctla-4 antibodies for treatment of cancer
DE69905170T2 (en) THIAZOLOPYRIMIDINDERIVATE
GEP20074024B (en) Polyalkylene glycol comprising a radical for conjugation of biologically active compound
BRPI0407583A (en) clearly and stable ophthalmic solution
ATE504308T1 (en) ANTIMICROBIAL CATIONIC PEPTIDES AND FORMULATIONS CONTAINING SAME
WO1998033509A3 (en) Useful properties of human lactoferrin and variants thereof
UA88463C2 (en) Pharmaceutical composition comprising compound i and method of treating hiv infection
DE60216305D1 (en) COMPOSITIONS FOR THE ADMINISTRATION OF MEDICINAL COMBINATIONS
DE10084671T1 (en) Pharmaceutical compositions
BR0008228A (en) Compositions of n-benzoyl staurosporine spontaneously dispersible
BR0213379A (en) Spill-resistant formulation of taste masking
BR9712498A (en) Alkoxylated aminequaternized detergent ingredients
YU13301A (en) Muscarinic agonists and antagonists
DE69907926D1 (en) 1,2,4-TRIAZOL-3-THION COMPOUNDS
RS49599B (en) Use of h+, k+ -atpaze inhibitors and glucocortifoids and pharmaceutical formulation
EP0916670A3 (en) Pyrrolo-(3,2-b) pyridines and their use as 5-HT1F agonists

Legal Events

Date Code Title Description
8364 No opposition during term of opposition